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BACKGROUND: Fewer children than adults have been affected by the COVID-19 pandemic, and the clinical manifestations are
distinct from those of adults. Some children particularly those with acute or chronic co-morbidities are likely to develop critical
illness. Recently, a multisystem inflammatory syndrome (MIS-C) has been described in children with some of these patients
requiring care in the pediatric ICU.
METHODS: An international collaboration was formed to review the available evidence and develop evidence-based guidelines for
the care of critically ill children with SARS-CoV-2 infection. Where the evidence was lacking, those gaps were replaced with
consensus-based guidelines.
RESULTS: This process has generated 44 recommendations related to pediatric COVID-19 patients presenting with respiratory
distress or failure, sepsis or septic shock, cardiopulmonary arrest, MIS-C, those requiring adjuvant therapies, or ECMO. Evidence to
explain the milder disease patterns in children and the potential to use repurposed anti-viral drugs, anti-inflammatory or anti-
thrombotic therapies are also described.
CONCLUSION: Brief summaries of pediatric SARS-CoV-2 infection in different regions of the world are included since few registries
are capturing this data globally. These guidelines seek to harmonize the standards and strategies for intensive care that critically ill
children with COVID-19 receive across the world.
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IMPACT:
● At the time of publication, this is the latest evidence for managing critically ill children infected with SARS-CoV-2.
● Referring to these guidelines can decrease the morbidity and potentially the mortality of children effected by COVID-19 and its
sequalae.
● These guidelines can be adapted to both high- and limited-resource settings.
INTRODUCTION
In early December 2019, a novel coronavirus causing pneumonia
was first reported in Wuhan, China and rapidly spread globally.
Given the pathogenicity, high transmission, asymptomatic carrier
rates, and global lack of human immunity to this virus, the World
Health Organization pronounced a pandemic on March 11, 2020.
Despite the aggressive nature of the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), children have been
minimally affected by the disease.
At the time of publication, 8.4 million infections have been
confirmed and 450,835 total deaths have been reported.1 The
epidemiology of infection rates by age and mortality are difficult
to identify globally, but pediatric cases have been relatively few.
Two large studies, from China and the United States, have the best
pediatric data to date. The largest pediatric review reported 2143
children from China (34.1% laboratory confirmed and 65.9%
suspected cases as of February 7, 2020), 5.6% children had severe
respiratory disease, 0.6% developed acute respiratory distress
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syndrome (ARDS), and 1 died.2 In contrast, 18.5% of adults had
developed severe or critical illness.2 In the United States, pediatric
patients made up only 1.7% of total cases from February 12 to
April 2; only 20% of these required hospitalization, 2% required
intensive care unit (ICU) admissions and three died.3 Both studies
noted that patients under 1 year of age were at greatest risk of
hospitalization and males accounted for 57% of cases.2,3 For those
patients where data were recorded, nearly a quarter of patients
had an underlying medical condition.3 Factors associated with
worse outcomes included younger age, underlying pulmonary
conditions, and immunocompromised states.4 The median age of
children in China was 7 years2,5 and in the United States was 11
years,3 suggesting regional differences in age distribution. Most
children therefore are asymptomatic or have mild to moderate
symptoms and the case fatality rate (CFR, 0–0.2%) in children is
much lower as compared to adults (CFR 2.3%).6
Common signs and symptoms among pediatric patients include
fever, cough, myalgias, sore throat, rhinorrhea, headache, short-
ness of breath, diarrhea, vomiting, tachypnea, and tachycardia.2,3,5
Gastrointestinal symptoms of vomiting and diarrhea appear to be
more common in pediatric patients as compared to adults.4,6,7
Adult patients that progress to severe disease often develop
dyspnea 8 days after disease onset and within 48 h can progress
to ARDS and multisystem organ dysfunction.8 Other findings in
critically ill patients include shock, encephalopathy, myocardial
dysfunction, heart failure, coagulopathy, and acute renal injury.2
Patients with severe COVID-19 appear to have a cytokine storm
profile similar to hemophagocytic lymphohistiocytosis.7 Recently,
a Multisystem Inflammatory Syndrome in Children (MIS-C) has also
been described and patient presentations range from mild
inflammation to severe shock with multiorgan involvement.
The progression of this pandemic in the ensuing months is
unclear and pediatric intensivists globally will need to be aware of
signs, symptoms, and treatments for COVID-19. The objective of
this international collaboration is to present management
strategies for critically ill pediatric patients infected with COVID-
19 in both high- and limited-resource settings.
Evaluation of minimal disease burden in children
Why are children relatively protected from COVID-19 illnesses?
Several theories have been proposed although scientific knowl-
edge in this regard is still evolving.
SARS-CoV-2 spike protein binds to angiotensin-converting enzyme
II (ACE2) receptor to infect cells.9 ACE2 is expressed in the type II
alveolar epithelial cells in the lungs, myocardial cells, esophageal, and
ileocolic epithelial cells, and may also play a role in the coagulation
system.10 The organotypic expression of this receptor may explain
the presenting signs and symptoms of patients with COVID-19. An
interplay between the renin-angiotensin system (RAS) and various
proteins may increase or decrease inflammation in lung injury.10–13
Prevalent use of ACE-inhibitors (ACEi) or angiotensin-receptor
blockers (ARB) in adults increases ACE2 expression, which may allow
SARS-CoV-2 entry into type II alveolar cells leading to worsening lung
disease.10,11 Conversely, other studies suggest that ACEi and ARBs
diminish Angiotensin II production which in turn attenuates lung
inflammation and injury.10,11 Relative absence of ACE2 expression in
children is currently touted as one theory why children are protected
from severe COVID-19 disease.14 Animal models demonstrate that
levels of ACE2 receptor vary with development and by sex.15,16
Children from 4 to 18 years of age also have higher ACE activity than
adults,17 which may be protective.
Age-based differences in immunity and inflammatory responses
across the lifespan could also explain these outcomes. Specifically,
lymphopenia occurred in only 3% of pediatric patients18 but 80%
of critically ill adults.8 Similar inferences about inflammatory
markers such as C-reactive protein or procalcitonin are more
difficult to draw at this time. Lymphopenia may contribute to the
inability to clear SARS-CoV-2 infection.
Another hypothesis is the antioxidant effects of melatonin to
attenuate the inflammatory injury occurring from viral
infections.19,20 Although melatonin may not decrease viral
replication, it indirectly regulates ACE2 and may impact the ability
of SARS-CoV-2 to enter, infect, and replicate.19 Ultimately,
melatonin may prolong a patient’s survival allowing the indivi-
dual’s immune system to eradicate the virus. Similar to ICU
supportive care, melatonin affords the patient time to recover.
Interestingly, the nighttime concentrations of melatonin in
children are significantly higher than adults.20 Thus, the direct
antioxidant effects of melatonin coupled with its effects on ACE2
receptors may play a protective effect in pediatric patients.
Understanding why children are relatively protected from
severe SARS-CoV-2 infection may help us develop targeted drugs
for symptomatic adult and pediatric patients.
METHODS
Pediatric intensivists with many years of clinical experience and
academic backgrounds were invited from across the globe to
develop these guidelines. Authors from both high- and limited-
resource settings and all regions of the world (except Oceania) are
represented. All contributing authors were assigned to various
recommendation sections along with writing the specific section for
their global region. Given the paucity of data in pediatric patients to
date, a systematic review with meta-analysis of multiple studies and
case series could not be used to evaluate the strength of each
recommendation. The authors therefore have identified relevant
adult and pediatric studies along with management guidelines from
other leading organizations, e.g. the World Health Organization, and
have extracted the best current evidence and guidelines to support
their recommendations. Each guideline is followed by a Strong,
Weak, Best practice, or Insufficient evidence recommendation (Table 1)
and the rationale for each recommendation is included in the body
of the manuscript. Recommendations could not be formulated using
the Evidence to Decision framework (EtD) due to the paucity of
relevant evidence regarding COVID-19 in pediatric patients and the




Mild respiratory disease: Pediatric patients presenting with mild
illness can be discharged and monitored at home. The family
should be advised to strictly adhere with quarantine guidelines,
use acetaminophen or paracetamol as a first-line agent for fever
control (see “Pharmacologic treatment” section for further
discussion), and to monitor the progression of clinical symptoms.
Severe respiratory disease: WHO defines severe respiratory
distress in children presenting with tachypnea and any of the
following: central cyanosis or hypoxemia (oxygen saturation
[SpO2] < 90%), grunting, inability to breastfeed or drink, lethargy,
unconsciousness, or convulsions.21 Age-specific tachypnea defini-
tions are respiratory rate ≥ 60/min in children < 2 months of age,
≥50/min in children 2–11 months of age, ≥40/min in children 1–5
years of age.21
Acute respiratory distress syndrome: Worsening respiratory
symptoms 1 week after disease onset due to SARS-CoV-2 with
new opacities on chest imaging not explained by cardiac failure or
volume overload and with a partial pressure of oxygen (PaO2) to
fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg, or an SpO2/
FiO2 < 264 during noninvasive ventilation, or an oxygenation
index > 4, or an oxygen saturation index (OSI) > 5 during invasive
mechanical ventilation are concerning for ARDS. Oxygen satura-
tion index can be calculated based on pulse oximeter information
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Table 1. Recommendations for the management of children infected with COVID-19.
Recommendation Strength
Ventilation
1. In children with COVID-19 infection and hypoxemia, begin supplemental oxygen therapy by low-flow nasal cannula
when oxygen saturations (SpO2) are <90%. If the patient continues with hypoxemia, oxygen delivery via a face mask
with reservoir bag should be initiated.
Strong
2. Children with COVID-19 that remain with increased work of breathing and hypoxemia should be escalated to high flow
nasal cannula (HFNC) if available. Patients with progressive respiratory distress or where HFNC is unavailable can be
escalated to noninvasive positive pressure ventilation (NIPPV), bubble continuous positive airway pressure (bCPAP) or bi-
level positive airway pressure (BiPAP).
Strong
3. Children with COVID-19 failing NIPPV should be escalated to mechanical ventilation. Strong
4. In children with COVID-19 requiring intubation, the procedure should be done by a trained and skilled health-care
provider.
Strong
5. Children with COVID-19 requiring intubation should be intubated with a cuffed endotracheal tube. Strong
6. For children with COVID-19 requiring intubation, use of video laryngoscopy should be considered for intubation. Weak
7. Personal protective equipment (PPE) should be worn for intubation and extubation of all children with COVID-19. Strong
8. For children with COVID-19 requiring mechanical ventilation, tidal volumes should be limited to 6ml/kg. Weak
9. For children with COVID-19 requiring mechanical ventilation, positive end expiratory pressure (PEEP) titration should be
individualized to each patient and their phase of ARDS.
Weak
10. For children with COVID-19 requiring mechanical ventilation, prone position should be considered in patients with
ARDS and severe hypoxemia.
Weak
11. For children with COVID-19 requiring mechanical ventilation with refractory hypoxemia, use of Inhaled nitric oxide is
not recommended.
Insufficient evidence
12. For children with COVID-19 requiring mechanical ventilation, high-frequency oscillatory ventilation (HFOV) is not
recommended for routine application but may be considered in select cases.
Insufficient evidence
Hemodynamic support
13. For children with COVID-19 and shock admitted to health systems with PICU availability (ventilatory support and access
to vasoactive amines), administer bolus fluids, 10–20ml/kg per bolus up to 40–60ml/kg, over the first hour of
resuscitation.
Weak
14. For children with COVID-19 and shock admitted to health systems without PICU availability (no ventilatory support and
access to vasoactive amines):
a. Patients without hypotension, no fluid bolus should be administered, and maintenance fluids should be initiated. Strong
b. Patients with hypotension, administer bolus fluids, 10–20ml/kg per bolus up to 40ml/kg, over the first hour of
resuscitation.
Weak
15. In children with COVID-19 and shock, crystalloid solutions should be administered, instead of colloids, for the initial
fluid resuscitation. Specifically, we recommend use of balanced solutions over 0.9% saline.
Weak
16. In children with COVID-19 and shock, age-appropriate mean arterial pressure (MAP) should be targeted. In settings
where accurate MAPs cannot be easily obtained, systolic blood pressure is an acceptable option.
Strong
17. In children with COVID-19 and shock, consider the use of advanced hemodynamic variables, when available
(measurements of cardiac index, systemic vascular resistance, and central venous oxygen saturation); these along with
clinical variables at the bedside can guide resuscitation.
Weak
18. In children with COVID-19 and shock, in addition to clinical evaluation, trends in blood lactate levels can help guide
resuscitation.
Weak
19. In children with COVID-19 and shock, epinephrine or norepinephrine should be administered, instead of dopamine.
Diluted solution can be initiated through a peripheral intravenous catheter if central venous access is not available.
Best practice
20. In children with COVID-19 and shock who need high doses of catecholamines, consider initiating vasopressin. Best practice
21. In children with COVID-19 and shock, recommendations regarding the use of inodilators cannot be made. But in clinical
practice, inodilators such as milrinone, dobutamine or levosimendan could be used when there are signs of tissue
hypoperfusion and cardiac dysfunction, despite high doses of catecholamines.
Best practice
22. In children with COVID-19 and refractory shock, consider anti-inflammatory doses of glucocorticoids. Insufficient evidence
23. In a pediatric patient with COVID-19 and severe disease, a thorough cardiac evaluation should be conducted including
an EKG, echocardiography and cardiac biomarker levels (troponin, CK and CK MB).
Strong
24. Glucocorticoid anti-inflammatory therapy and intravenous immunoglobulin (IVIG) are potential suggested treatments
for children with COVID-19-related myocarditis.
Insufficient evidence
Adjuvant therapy
25. Consider anticoagulation therapy in children with COVID-19 with:
a. Mild risk of venous thromboembolism (VTE) (i.e. those with indwelling central or peripheral central venous
catheters or severely ill with no hyperinflammatory status and with no risk of thrombosis), consider:
i. Subcutaneous enoxaparin < 2 months: 0.75mg/kg/dose q12 h; ≥2 months: 0.5 mg/kg/dose q12 h
ii. Anti-Xa factor target: 0.3–0.5 IU/ml
b. Children with COVID-19 with high risk of VTE (i.e. critically ill, hyperinflammatory state—C-reactive protein > 150
mg/l, D-dimer > 1500 ng/ml, IL-6 > 100 pg/ml, ferritin > 500 ng/ml, or past history of thromboembolic events)
consider:
Weak
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without blood gas measurements; therefore, it can be used in the
resource-limited environment and may facilitate early recognition
of ARDS. Pediatric-specific and resource-limited setting definitions
have also been defined previously.22,23
Treatment recommendations for oxygen therapy and noninvasive
mechanical support.
1. In children with COVID-19 infection and hypoxemia, begin
supplemental oxygen therapy by low-flow nasal cannula
when oxygen saturations (SpO2) are <90%.
24 If the patient
continues with hypoxemia, oxygen delivery via a face
mask with reservoir bag should be initiated (Strong
recommendation).
2. Children with COVID-19 that remain with increased work
of breathing and hypoxemia should be escalated to High
Flow Nasal Cannula (HFNC) if available. Patients with
progressive respiratory distress, or where HFNC is unavail-
able, can be escalated to noninvasive positive pressure
ventilation (NIPPV), bubble continuous positive airway
Table 1. continued
Recommendation Strength
i. Subcutaneous enoxaparin < 2 months: 1.5 mg/kg/dose q12 h; ≥2 months: 1 mg/kg/dose q12 h
ii. Anti-Xa factor target: 0.5–1 IU/ml
26. In critically ill children with COVID-19, thrombocytopenia-associated multiple organ failure (TAMOF: platelet counts of
less than 100 × 109/L and two or more failing organs) and acquired ADAMTS-13 deficiency could indicate a thrombotic
microangiopathic process. For such patients, therapeutic plasma exchange may be beneficial in controlling the
hyperinflammatory and thrombotic state and reversing organ dysfunction.
Weak
27. For critically ill children with COVID-19, we suggest convalescent plasma treatment be offered only within a research
framework or on a compassionate basis.
Insufficient evidence
28. For children with COVID-19 admitted to the PICU, initiate enteral nutrition for patients with no contraindications, but
parenteral nutrition need not be initiated in the first 7 days of PICU admission.
Weak
29. For children with COVID-19 that develop fluid overload or renal dysfunction and are unresponsive to diuretic therapy
consider renal replacement therapy.
Weak
CPR/Resuscitation
30. Limit the number of personnel in the room for pediatric patients with COVID-19 that require cardiopulmonary
resuscitation.
Best practice
31. For COVID-19 pediatric patients that have arrested follow standard cardiac arrest guidelines for CPR ratios, and
treatments.
Best practice
32. For intubated patients, recommendations include:
a. Increase the FIO2 to 1.0.
b. Change mode to Pressure Control Ventilation and limit pressure as needed to generate adequate chest rise.
c. Adjusting the trigger to Off will prevent the ventilator from auto-triggering with chest compressions and may
prevent hyperventilation.
d. Adjust respiratory rate to 10/min for adults and children.
e. Adjust PEEP level to balance lung volumes and venous return.
f. If return of spontaneous circulation is achieved, set ventilator settings as appropriate to patient’s clinical condition
Best practice
33. Patients in prone position at time of cardiac arrest without an advanced airway should be placed supine. Intubated
patients, however, can remain prone and CPR can be initiated while the patient is prone.
Best practice
34. For children with COVID-19 that require PICU admission, address the goals of care with the parents or proxy as life-
sustaining therapies are being escalated.
Best practice
ECMO considerations
35. ECMO should be considered in COVID-19-infected pediatric patients to manage ARDS and/or cardiac failure
(myocarditis, arrhythmias, pulmonary embolism).
Strong
36. Strict selection criteria for both Veno-Arterial (VA) and Veno-Venous (VV) ECMO should be applied in order to utilize
ECMO for those patients most likely to benefit from the procedure.
Strong
Pediatric Multisystem Inflammatory Syndrome—Children (MIS-C)
37. Supportive management and advanced monitoring should be provided (see “Hemodynamic support“ section).
38. Early EKG and echography for cardiac function and coronary flow should be completed. Best practice
39. Imaging studies should include chest X-ray, abdominal ultrasound, chest CT. Best practice
40. A multidisciplinary team, including Intensive Care, Cardiology, Infectious Disease and Rheumatology, should manage
these patients.
Best practice
41. Laboratory evaluation should include testing for SARS-CoV-2, biomarkers for inflammation, and multiorgan system
dysfunction.
Best practice
42. Initiate empirical antibiotics until bacterial sepsis, staphylococcal or streptococcal syndrome are excluded. Best practice
43. Medications to consider for management of MIS-C include solumedrol, IVIG, anticoagulants (see “Adjuvant therapy”
section), and biologics (e.g. Anakinra, IL-6 inhibitors) and should be based on patient’s severity of illness using a
multidisciplinary approach.
Insufficient evidence
44. For patients that specifically meet Kawasaki disease criteria (classic or atypical), administer IVIG (2 g/kg) and high-dose
aspirin (50mg/kg).
Strong
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pressure (bCPAP) or bi-level positive airway pressure (BiPAP)
(Strong recommendation).
Rationale. Patients with respiratory distress should be treated
when oxygen saturations are <90%.25 HFNC or NIPPV are safe and
efficacious modes of respiratory support in pediatric patients and
may provide adequate respiratory support to prevent the need for
invasive mechanical ventilation. At a time when there is a global
shortage of ventilators, particularly in resource-limited settings,
alternative methods of respiratory support such as bCPAP should
be considered. WHO recommends the use of bubble CPAP for
treatment of COVID-19-infected children with hypoxemia, severe
pneumonia and/or ARDS based on trials in Bangladesh and
Ghana.26–29 These studies demonstrate improved outcomes in
pediatric patients treated with locally developed bCPAP devices.
Thus, in situations where mechanical ventilation might not be
available, bCPAP may be used for newborns and children with
severe hypoxemia, and may more readily be available in resource-
limited settings.26 A recent systematic review revealed that the
use of HFNC and bCPAP in children with severe pneumonia
decreased the need for intubation and mechanical ventilation;
younger children in particular had a greater benefit from the use
of bCPAP.29 It is imperative that patients treated with either HFNC
or NIPPV should be closely monitored for clinical deterioration.
Finally, since all forms of respiratory support are at risk of
aerosolization, health-care providers must assure airborne pre-
cautions and proper personal protective equipment is used.
Treatment recommendations for invasive mechanical ventilation.
3. Children with COVID-19 failing NIPPV should be escalated to
invasive mechanical ventilation (Strong recommendation).
4. In children with COVID-19 requiring intubation, the proce-
dure should be done by a trained and skilled health-care
provider (Strong recommendation).
5. Children with COVID-19 requiring intubation should be
intubated with a cuffed endotracheal tube (Strong recom-
mendation).
6. For children with COVID-19 requiring intubation, use of
video laryngoscopy should be considered for intubation
(Weak recommendation).
7. Personal protective equipment (PPE) should be worn for
intubation and extubation of all children with COVID-19
(Strong recommendation).
8. For children with COVID-19 requiring mechanical ventila-
tion, tidal volumes should be limited to 6ml/kg (Weak
recommendation).
9. For children with COVID-19 requiring mechanical ventila-
tion, positive end expiratory pressure (PEEP) titration should
be individualized to each patient and their phase of ARDS
(Weak recommendation).
10. For children with COVID-19 requiring mechanical ventila-
tion, prone position should be considered in patients with
ARDS and severe hypoxemia (Weak recommendation).
11. For children with COVID-19 requiring mechanical ventilation
with refractory hypoxemia, use of inhaled nitric oxide is not
recommended (Insufficient evidence).
12. For children with COVID-19 requiring mechanical ventila-
tion, high-frequency oscillatory ventilation (HFOV) is not
recommended for routine application but may be consid-
ered in select cases (Insufficient evidence).
Rationale. Patients with progressive hypoxemia, altered mental
status, or continued increased work of breathing on NIPPV should
undergo endotracheal intubation (e.g. evolving ARDS). Multiple
intubation attempts can result in poorer outcomes for the
patient30 and place the provider at greater risk of exposure to
COVID-19; therefore, intubation by the most-skilled provider is
recommended. Before endotracheal intubation, bag-mask respira-
tory assistance may become an aerosol-generating procedure;
therefore, rapid sequence intubation (RSI) using muscle relaxant is
recommended. Pre-oxygenation with 100% oxygen (unless con-
traindicated, e.g. cyanotic heart lesion patients) is recommended
to minimize hypoxia with RSI; children are at great risk of hypoxia
due to a smaller functional residual capacity. Video laryngoscopy,
if available, can be used to increase the distance between the
patient and provider.31 Once the patient is intubated, the
endotracheal tube cuff must be inflated immediately to prevent
aerosolization. Endotracheal intubation is an aerosol-generating
procedure; the provider therefore requires full PPE to protect
himself/herself. PPE includes disposable fluid-resistant long-
sleeved gowns, goggles or disposable full-face shields, and N95
masks. If available, a powered air-purifying respirator (PAPR) can
be used in place of an N95 mask. Disposable operating room caps
should be worn to reduce contaminating hairs by droplets.32
In order to provide further protection of health-care workers,
other procedures have also been introduced, including an acryl
intubation box,33 plastic drapes,30 as well as mask-over-tube
technique.34 Use of hydrophobic viral filters placed at the
ventilator outlets and inline closed suction are suggested to
minimize the risk of transmission. Extubation is also an aerosol-
generating procedure; therefore, PPE must be worn.
General management guidelines or protocols35 for mechanical
ventilation in ARDS can be applied to the COVID-19 patients with
respiratory failure. A low tidal volume, 4−6ml/kg for ideal body
weight, lung protective strategy is usually recommended.35 However,
larger tidal volumes are frequently used in pediatric intensive care
units (PICU) around the world36; therefore, it is advised to continue to
use tidal volumes familiar to each institution. A meta-analysis of
observational studies in children did not demonstrate a survival
benefit by reducing tidal volumes37 and a retrospective analysis of
ARDS patients at a single center also did not show a relation
between tidal volumes and outcomes.38
Regarding the PEEP level, the experience in adult COVID-19
patients in Italy does not advise the use of higher PEEP routinely39
which varies from previous recommendations of PEEP use in ARDS.35
In the early phase of respiratory failure with COVID-19, the majority of
patients exhibit critical hypoxemia due to increased intrapulmonary
shunt fraction; however, the lung compliance is relatively main-
tained.39 In this situation, applying high PEEP may have detrimental
effects, and applying relatively low PEEP and accepting lower oxygen
saturations (80s to 90s) may be advised if the patient has single organ
failure of the lungs. In the later phase, the pathophysiology may
change to typical ARDS39 requiring a higher PEEP. Individualized
titration of PEEP is recommended and the patient’s hemodynamics
must be monitored closely with increasing PEEP.
Studies have demonstrated that prone positioning can improve
oxygenation.40 However, this strategy should be implemented only by
teams that routinely prone patients. Inhaled nitric oxide may improve
oxygenation, but no studies to date have demonstrated a survival
benefit.41 High-frequency oscillatory ventilation (HFOV) can be
considered for refractory respiratory failure, but no clear data exist
to support its use in COVID-19 patients. Hence, conventional
mechanical ventilation using individualized PEEP is advised42; patients
with preserved compliance may not require high PEEP whereas those
with low lung compliance will benefit from more PEEP.
Finally, although not listed as a recommendation, a conservative
fluid strategy should be used in patients with ARDS if the patient’s
hemodynamics will allow fluid restriction.
If available, extracorporeal membrane oxygenation (ECMO) may be
considered in patients with continued severe hypoxemia despite
maximal support (see “ECMO considerations” section).
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Clinical presentation. Clinical presentation of children with
COVID-19 can range from tachycardia to classic signs of shock
and heart failure. The presence of tachycardia varies from 6 to
42%.5,43
Reports in adult patients indicate that patients with myocardial
injury may have arrhythmias and myocarditis. The presence of
myocardial injury and increased cardiac biomarkers are associated
with worse outcomes with a tenfold increase in mortality.44
Cardiac injury can be detected by elevated cardiac biomarkers,
such as troponin, creatine kinase (CK), and its isoenzyme MB,
electrocardiogram (EKG) and echocardiographic abnormalities.
Cardiac enlargement can be evidenced in chest X-ray or CT
scan.45,46 Pediatric patients at risk of developing myocarditis
include those with comorbidities, such as heart disease, or those
who progress to the severe hyperinflammatory phase.
Treatment recommendations for shock.
13. For children with COVID-19 and shock admitted to health
systems with PICU availability (ventilatory support and
access to vasoactive amines), administer bolus fluids,
10–20ml/kg per bolus up to 40–60ml/kg, over the first
hour of resuscitation47 (Weak recommendation).
14. For children with COVID-19 and shock admitted to health
systems without PICU availability (no ventilatory support
and access to vasoactive amines)47:
Patients without hypotension, no fluid bolus should be
administered and maintenance fluids should be initiated
(Strong recommendation).
Patients with hypotension, administer bolus fluids,
10–20ml/kg per bolus up to 40ml/kg, over the first hour
of resuscitation (Weak recommendation).
15. In children with COVID-19 and shock, crystalloid solutions
should be administered, instead of colloids, for the initial
fluid resuscitation. Specifically, we recommend use of
balanced solutions over 0.9% saline (Weak recommendation).
16. In children with COVID-19 and shock, age-appropriate mean
arterial pressure (MAP) should be targeted. In settings where
accurate MAPs cannot be easily obtained, systolic blood
pressure is an acceptable option (Strong recommendation).
17. In children with COVID-19 and shock, consider the use of
advanced hemodynamic variables, when available (mea-
surements of cardiac index, systemic vascular resistance,
and central venous oxygen saturation); these along with
clinical variables at the bedside can guide resuscitation
(Weak recommendation).
18. In children with COVID-19 and shock, in addition to clinical
evaluation, trends in blood lactate levels can help guide
resuscitation (Weak recommendation).
19. In children with COVID-19 and shock, epinephrine or
norepinephrine should be administered, instead of dopa-
mine. Diluted solution can be initiated through a peripheral
intravenous catheter if central venous access is not available
(Best practice recommendation).
20. In children with COVID-19 and shock who need high doses
of catecholamines, consider initiating vasopressin (Best
practice recommendation).
21. In children with COVID-19 and shock, recommendations
regarding the use of inodilators cannot be made. But in
clinical practice, inodilators such as milrinone, dobutamine
or levosimendan could be used when there are signs of
tissue hypoperfusion and cardiac dysfunction, despite high
doses of catecholamines (Best Practice recommendation).
22. In children with COVID-19 and refractory shock, consider anti-
inflammatory doses of glucocorticoids (Insufficient evidence).
23. In a pediatric patient with COVID-19 and severe disease, a
thorough cardiac evaluation should be conducted including
an EKG, echocardiography, and cardiac biomarker levels
(troponin, CK and CK MB) (Strong recommendation).
24. Glucocorticoid anti-inflammatory therapy and intravenous
immunoglobulin (IVIG) are potential suggested treatments
for children with COVID-19-related myocarditis (Insufficient
evidence).
Rationale. The need for bolus fluid administration should be
guided by frequent clinical assessments (heart rate, blood
pressure, capillary refill, level of consciousness, urine output),
serial serum lactate levels, and advanced hemodynamic monitor-
ing when available. In the presence of fluid overload, (signs of
pulmonary edema and/or hepatomegaly), fluid resuscitation
should be reassessed. In settings with advanced supportive care
availability, recent studies show no difference in mortality
between the restrictive and permissive fluid resuscitation strate-
gies.47–50 The FEAST trial done in Africa evaluating fluid
resuscitation in limited-resource settings demonstrates the need
to be cautious of aggressive fluid resuscitation.51
Studies demonstrate no outcome benefits for patients resusci-
tated with crystalloid over colloid solutions. Crystalloid solutions
are recommended based on lower cost, greater availability, and
the transfusion risk associated with colloid use.
Although blood lactate is not considered a direct measure of
tissue perfusion, high lactate is associated with worse outcomes in
children.52 Additionally, adult data demonstrated significantly
lower mortality and improvement in other outcomes when
resuscitation was guided by serial lactate measurements.53–56
Persistently elevated blood lactate levels may indicate incomplete
hemodynamic resuscitation and should trigger efforts to restore
adequate tissue perfusion and establish hemodynamic stability.
For inotropic support, epinephrine or norepinephrine should be
chosen as the first-line vasoactive infusion guided by clinical
preferences, individual patient physiology, and local system
factors. Both have inotropic and vasopressor effects and are
effective in treating children with fluid refractory shock. Epinephr-
ine should be considered as the first-line agent in patients with
myocardial dysfunction and norepinephrine for patients with low
systemic vascular resistance, as recommended in Surviving Sepsis
Campaign (SSC) guidelines.47 Institutional practices and the
availability of vasopressin should determine if and when it can
be initiated. Although there are no RCTs for inodilators in children
with shock, they should be considered in patients with
myocarditis or low cardiac output syndrome. Glucocorticoids
could also be considered for patients with refractory shock (see
“Pharmacologic treatment” section for further discussion).
For patients with signs of myocarditis, in addition to supportive
treatment, some anecdotal reports in adult patients with COVID-
19 and myocarditis suggest IVIG therapy.57,58
Adjuvant therapy
Clinical presentation. In this section, we discuss several important
supportive therapies that may be applicable in critically ill children
with COVID-19. Many of these therapies are described in critically
ill adults but their description in the pediatric population remains
limited. These therapies include the management of the
prothrombotic state that occurs frequently in adult patients with
COVID-19, convalescent plasma infusion, nutritional therapy, and
renal replacement therapies.
Treatment recommendations.
25. Consider anticoagulation therapy for children with COVID-
19 (Weak recommendation):
a. Mild risk of venous thromboembolism (VTE) (i.e. those
with indwelling central or peripheral central venous
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catheters59,60 or severely ill with no hyperinflamma-
tory status and with no risk of thrombosis), consider:
i.
Subcutaneous enoxaparin < 2 months: 0.75 mg/kg/dose q12 h;
≥2 months: 0.5 mg/kg/dose q12 h
ii.
Anti-Xa factor target: 0.3–0.5 IU/ml
b. Children with COVID-19 with high risk of VTE (i.e.
critically ill, hyperinflammatory state—C-reactive pro-
tein > 150mg/l, D-dimer > 1500 ng/ml, IL-6 > 100 pg/
ml, ferritin >500 ng/ml, or past history of thromboem-
bolic events) consider:
i.
Subcutaneous enoxaparin < 2 months: 1.5 mg/kg/dose q12 h;
≥2 months: 1 mg/kg/dose q12 h
ii.
Anti-Xa factor target: 0.5–1 IU/ml
26. In critically ill children with COVID-19, thrombocytopenia-
associated multiple organ failure (TAMOF: platelet counts of
less than 100 × 109/l and two or more failing organs), and
acquired ADAMTS-13 deficiency could indicate a thrombotic
microangiopathic process. For such patients, therapeutic
plasma exchange may be beneficial in controlling the
hyperinflammatory and thrombotic state and reversing
organ dysfunction61,62 (Weak recommendation).
27. For critically ill children with COVID-19, we suggest
convalescent plasma treatment be offered only within a
research framework or on a compassionate basis (Insufficient
evidence).
28. For children with COVID-19 admitted to the PICU, initiate
enteral nutrition for patients with no contraindications, but
parenteral nutrition should not be initiated in the first 7 days
of PICU admission (Weak recommendation).
29. For children with COVID-19 that develop fluid overload or
renal dysfunction and are unresponsive to diuretic therapy
consider renal replacement therapy (Weak recommendation).
Rationale. High rates of venous thromboembolism (e.g., central
line thrombosis and vascular occlusive events such as ischemic
limbs and strokes) have been observed in critically ill COVID-19
adult patients.63–68 Although COVID-19 pediatric patients have not
experienced thrombotic complications, the coagulation abnorm-
alities reported are consistent with a hyperinflammatory pro-
thrombotic state: elevated levels of D-dimer, C-reactive protein,
procalcitonin, IL-6, and thrombocytopenia.18,69–71 A hyperinflam-
matory response to the infection may be the main pathogenic
mechanism involved.72,73 In adults with COVID-19 infection,
heparin seemed to decrease mortality in those patients with high
D-dimer.74,75 Laboratory tests to consider in patients with
thrombotic complications include: platelet count, PTT, fibrinogen,
antithrombin III, ADAMTS-13, IL-6, D-dimer, C-reactive protein,
procalcitonin, ferritin, plasma-free hemoglobin, schistocytes, LDH,
haptoglobin, and thromboelastography (TEG).
Therapeutic plasma exchange has been proposed for patients
with fulminant COVID-19 infection since it offers benefit on
multiple levels by removing inflammatory cytokines, stabilizing
endothelial membranes, and resetting the hypercoagulable
state.76 However, use of plasma exchange therapy in children
with COVID-19 has not been reported to date.
In previous pandemics (e.g., SARS, H1N1 2009, MEWRS-CoV),
convalescent plasma treatments were utilized as part of the
management strategies.77–79 Because convalescent plasma can
potentially suppress viremia in COVID-19,80 there is increasing
description of convalescent plasma treatment, albeit mainly as
case reports and case series.
To date, there are no specific nutrition guidelines for critically ill
children with COVID-19. The Society of Critical Care Medicine
together with American Society for Parenteral and Enteral
Nutrition have provided some guidance on the nutrition therapy
for critically ill adult patients.81
Current available evidence from critically ill adults with COVID-
19 found that acute kidney injury (AKI) is not a common
phenomenon82 and no recommendations were made in the adult
COVID-19 surviving sepsis guidelines.83 To date, there are no
specific data on the incidence of AKI in critically ill children with
COVID-19.
Cardiopulmonary resuscitation (CPR)
Clinical presentation. In pediatric patients infected with COVID-19
that are pulseless due to asystole, pulseless electrical activity (PEA),
ventricular fibrillation, or pulseless ventricular tachycardia, the
following recommendations should be considered.
Treatment recommendations.
30. Limit the number of personnel in the room for pediatric
patients with COVID-19 that require cardiopulmonary
resuscitation (Best practice recommendation).
31. For COVID-19 pediatric patients with cardiac arrest, follow
the standard cardiac arrest guidelines for CPR ratios, and
treatments (Best practice recommendation).
32. For intubated patients, recommendations include (Best
practice recommendation):
a. Increase the fractional inspired oxygen (FiO2) to 1.0.
b. Change mode to Pressure Control Ventilation and limit
pressure as needed to generate adequate chest rise.
c. Adjusting the trigger to Off will prevent the ventilator
from auto-triggering with chest compressions and
may prevent hyperventilation.
d. Adjust respiratory rate to 10/min for adults and
children.
e. Adjust PEEP level to balance lung volumes and venous
return.
f. If return of spontaneous circulation is achieved, set
ventilator settings as appropriate to patient’s clinical
condition.
33. Patients in prone position at the time of cardiac arrest
without an advanced airway should be placed supine.
Intubated patients however can remain prone and CPR can
be initiated while the patient is prone (Best practice
recommendation).
34. For children with COVID-19 that require PICU admission,
address the goals of care with the parents or proxy as life-
sustaining therapies are being escalated (Best practice
recommendation).
Rationale. The American Heart Association (AHA) has modified
conventional guidelines84 and released the following general
principles when administering CPR to patients with suspected
COVID-19. The guidelines have been modified to protect health-
care providers and reduce COVID-19 exposure. All rescuers must
don PPE to guard against both airborne and droplet particles.
Limiting personnel in the room is recommended. If available, use
of mechanical CPR devices on young adolescents instead of
manual chest compressions is recommended to protect rescuers.
To lower the aerosolization risk of COVID-19, patients should be
intubated with a cuffed endotracheal tube and connected to a
ventilator with an inline suction catheter and a high efficiency
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particulate air (HEPA) filter in the path of exhaled gas. If possible, an
HEPA filter should be attached to all manual or mechanical
ventilation devices (see “Ventilation” section regarding intubation).
For patients that are already intubated at the time of arrest, they
should remain on the ventilator with the HEPA filter to minimize
aerosolization. General ventilator principles are to optimize oxygena-
tion and venous return while minimizing hyperinflation.85
Patients who are prone at the time of arrest without an advanced
airway, the recommendation is to place them supine and continue
resuscitation. While the effectiveness of CPR in the prone position is
not completely known, for proned patients with an advanced airway,
avoid turning the patient to the supine position unless able to do so
without risk of equipment disconnections and aerosolization.
Instead, consider placing defibrillator pads in the anterior-posterior
position and provide CPR with the patient remaining prone with
hands in the standard position over the T7/10 vertebral bodies.86
Consider the appropriateness of starting and continuing CPR in
COVID-19 patients. It is reasonable to consider age, comorbidities,
and severity of illness in determining the appropriateness of
resuscitation and balance the likelihood of success against the risk
to rescuers and patients from whom resources are being diverted. It
is recommended to address the goals of care with parents (or proxy)
prior to an arrest situation.
ECMO considerations
Clinical presentation. In PICU patients with SARS-CoV-2 that
develop refractory hypoxemia or hypotension despite maximal
medical support, ECMO may be considered.
Treatment recommendations.
35. ECMO should be considered in COVID-19-infected pediatric
patients to manage ARDS and/or cardiac failure (myocardi-
tis, arrhythmias, pulmonary embolism) (Strong recommen-
dation).
36. Strict selection criteria for both Veno-Arterial (VA) and
Veno-Venous (VV) ECMO should be applied in order to
utilize ECMO for those patients most likely to benefit from
the procedure (Strong recommendation).
Rationale. The WHO,25 the Society of Critical Care Medicine83 and
Extracorporeal Life Support Organization87 have all recommended
the potential use of ECMO in severe cases of COVID-19. However,
at the time of submitting this publication, specific indications and
contraindications for its use in COVID-19 are scarce and outcome
data derived from China are not encouraging.88 However,
preliminary positive experiences in South Korea and Japan
suggest the use of ECMO to manage SARS-CoV-2-induced ARDS
and/or cardiac failure (myocarditis, arrhythmias, pulmonary
embolism) unresponsive to maximal medical therapy.89
Initiation and patient selection for both VA and VV ECMO should
not deviate from the existing guidelines.90 Early ECMO deploy-
ment is suggested to avoid progression to multiorgan failure.
Older age, presence of more than two comorbidities, immuno-
compromised state (lymphopenia) are not absolute contraindica-
tions; however, each case should be evaluated on an individual
basis.91,92 In a pandemic, ECMO should be initiated only at an
experienced center, but even in such centers the availability of
equipment and human capital should be considered prior to
deployment of such a resource-intensive intervention. Extracor-
poreal cardiopulmonary resuscitation (eCPR) should not be
initiated in less experienced centers or centers without an existing
eCPR program prior to the pandemic. As disease burden increases,
selection criteria for both respiratory and cardiac ECMO will
become more stringent in order to utilize ECMO for those patients
most likely to benefit. Given the pathophysiology of SARS-CoV-2 in
humans, children may have better outcomes than adult patients
and therefore may be a population in which ECMO resources
should be invested.
Pediatric multisystem inflammatory syndrome—children (MISC-C)
Clinical presentation/case definition. Potential presenting signs for
MIS-C are fever, fatigue, altered mental status, neck pain,
respiratory difficulty, chest pain, vomiting, diarrhea, abdominal
pain, rash, and conjunctivitis. Specifically, case definition of MIS-C
per the Center for Disease Control include the following93:
● Patient < 21 years of age presenting with fever (≥38.0 °C for ≥
24 h, or report of subjective fever lasting ≥24 h), altered
inflammations markers (C-reactive protein, erythrocyte sedi-
mentation rate, fibrinogen, procalcitonin, D-dimer, ferritin,
lactic acid dehydrogenase, or IL-6, elevated neutrophils,
reduced lymphocytes, low albumin), and clinically severe
illness requiring hospitalization, with two or more organs
being involved (cardiac, renal, respiratory, hematologic,
gastrointestinal, dermatologic or neurological); AND
● No other possible diagnoses (such as bacterial sepsis,
staphylococcal or streptococcal syndrome); AND
● Recent or current SARS-CoV-2 infection, positive reverse-
transcriptase polymerase chain reaction (RT-PCR) or serology
test, or COVID-19 exposure in a period of 4 weeks prior to
symptoms onset.
It must be noted that patient’s severity of illness in the hospital
may range from mild to severe. Multisystem Inflammatory
Syndrome should be considered in any pediatric death with
evidence of SARS-CoV-2 infection.
Treatment recommendations for patients with concern for MIS-C.
37. Supportive management and advanced monitoring should
be provided (see “Hemodynamic support” section).
38. Early EKG and echography for cardiac function and coronary
flow should be completed (Best practice recommendation).
39. Imaging studies should include chest X-ray, abdominal
ultrasound, chest CT (Best practice recommendation).
40. A multidisciplinary team, including Intensive Care, Cardiol-
ogy, Infectious Disease and Rheumatology, should manage
these patients (Best practice recommendation).
41. Laboratory evaluation should include testing for SARS-CoV-
2, biomarkers for inflammation, and multiorgan system
dysfunction (Best practice recommendation).
42. Initiate empirical antibiotics until bacterial sepsis, staphylo-
coccal or streptococcal syndrome are excluded (Best practice
recommendation).
43. Medications to consider for management of MIS-C include
solumedrol, IVIG, anticoagulants (see “Adjuvant therapy”
section), and biologics (e.g. Anakinra, IL-6 inhibitors) and
should be based on patient’s severity of illness using a
multidisciplinary approach (Insufficient evidence).
44. For patients that specifically meet Kawasaki disease criteria
(classic or atypical), administer IVIG (2 g/kg) and high-dose
aspirin (50 mg/kg) (Strong recommendation).
Rationale. Since the initial National Health Service alert in
England on April 26, multiple case reports have described children
presenting with Kawasaki disease-like features and hyperinflam-
matory shock.94–96 At the Italian epicenter of SARS-CoV-2, a 30-
fold increase was noted of children presenting with severe
Kawasaki-like disease,97 and New York city reported on 15 children
(ages 2–15 years) that required hospitalization (April 16−May 4)
for multisystem inflammatory syndrome. Soon after, a Health Alert
from the CDC93 described this disease entity and labeled it MIS-C.
These patients test positive for COVID-19 either by RT-PCR or
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serology suggesting a pathogenic link between SARS-CoV-2 and
MIS-C. The potential mechanism for the inflammation and
mediated organ damage is unclear at present.
Given the novelty of MIS-C, treatment recommendations and
best practices are based on treatments used in other aggressive
inflammatory disease processes. Institutions with high number of
MIS-C cases have developed institutional protocols regarding drug
dosing and regimens based on patient’s severity of illness, but no
definitive data exist to date.
Pharmacologic treatments
There is insufficient evidence to date to make any definitive
recommendations on pharmacologic therapies for pediatric
patients with SARS-CoV-2. Children are protected from COVID-19
in part because they have low ACE2, which are entry points for the
COVID-19 spike protein to attach and enter the host. Treatment of
fever with acetaminophen or paracetamol is prudent since the
impact of nonsteroidal anti-inflammatory drugs (NSAIDs) on
children with COVID-19 is unclear and being investigated. Because
children account for <0.1% of deaths from SARS-CoV-2, informa-
tion on COVID-19-specific pharmacologic treatments is extrapo-
lated from the adult Chinese, French, and Italian experience. The
first report from Wuhan, China on hospitalized adult patients with
SARS-CoV-2 revealed hyperferritinemic sepsis98 in those who died.
Fever developed on day 1, sepsis on day 10, ICU admission on day
12 (for ARDS), and death at 19 days. Hyperferritinemia on days 4
and 7 predicted mortality long before development of sepsis and
ICU admission. Progression to death was marked by increasing
ferritin, C-reactive protein, IL-6, LDH, and D-dimer levels.
Pharmacologic approach presently under study in adults99 has
been conceived to target a first phase of viral infection (antiviral
strategies), and then a second phase of hyperinflammatory
(corticosteroid and biologic strategies) and prothrombotic (antith-
rombotic strategies) host responses (Table 2).
Repurposed antiviral strategies for SAR-CoV-2. Repurposed anti-
viral agents include remdesivir (ebola), and lopinavir/ritinovir (HIV);
and repurposed immune-enhancing therapies include type I
interferons (multiple sclerosis), and passive immunization with
convalescent plasma. Effectiveness of these antiviral agents is best
when given early in the course of infection before day 4 of
symptoms. Use of immune-enhancing interferons is also likely to
have benefit when given before need of hospitalization. For
practical reasons, convalescent plasma should be reserved for
hospitalized patients. Unfortunately, the ongoing adult clinical
trials investigating the potential effectiveness of these therapies
mostly do not adhere to these biologically plausible timelines. It is
unlikely that their full benefit, if present, will be revealed in the
present ongoing adult studies. Pediatric dosing experience exists
for use of lopinavir/ritonavir (HIV), and type 1 interferons (chronic
active hepatitis).
Repurposed anti-inflammatory strategies. These strategies can be
considered when there is bedside evidence for hyperinflammation.
Adult studies are presently using some combination of ferritin
levels > 500, LDH > 300, and D-dimers > 1000 to identify eligible
patients. Anti-inflammatory agents with minimal immune-
suppressive effects that are under study include corticosteroids
(methylprednisone), interleukin 1 receptor antagonists, and inter-
leukin 6 receptor inhibitors. Use of these agents are more likely to
be beneficial if started when hyperferritinemia occurs, which started
at day 4 in the Wuhan experience. Therefore, monitoring ferritin
should begin at day 4 of illness and the therapies are given before
day 7 if hyperferritinemia occurs, and optimally before requiring
intensive care at day 12. It is important to note that the
hyperinflammatory response occurs in a minority of COVID-19
patients but is associated with the highest mortality. Unlike
antivirals, these anti-inflammatory therapies should be reserved
only for patients with hyperferritinemic inflammation. Pediatric
dosing experience exists with corticosteroids and interleukin 1
receptor antagonist protein (Systemic Juvenile Arthritis induced
Macrophage Activation Syndrome) and interleukin 6 inhibitors (CAR
T-cell therapy induced Cytokine Releasing Syndrome). These
therapies can and should also be considered for patients with
MIS-C.
REGIONAL EXPERIENCE
Several databases have recently begun tracking pediatric patients
affected by SARS-CoV-2 globally, but the authors gathered data
from best available resources for their respective regions.
Africa
Due to limited testing and difficulty in tracking cases, the data
from Africa are limited. But data that can be identified are listed
here. In Uganda, as of April 23, 63 cases have been confirmed, 9 of
which are children ≤19 years of age.100 It is unclear how many of
those patients may have required hospitalization.
In Zimbabwe, 203 total cases have been confirmed and the
number of pediatric cases is unknown as they did not require ICU
admission as of June 2. With widespread antibody screening now
being initiated in the country, more accurate numbers of infected
persons should be available. Based on National Institute for
Communicable Diseases (NICD) data from South Africa, as of April
19, 219 persons under 20 years of age were infected with COVID-
19 but PICU admission data were not available (communication
with Dr. Felicity Gumbo).
Asia
As of April 17, 82,000 cases of COVID-19 cases were confirmed in
China. Wuhan city has reported 50,333 cases with 600 of those
being pediatric patients.101,102 Only a small proportion of the
pediatric cases required PICU admission.71 Many patients that
developed critical illness had underlying pathologies, e.g. con-
genital heart disease, malnutrition.71 From the initial experience
described in China, pediatric patients were mainly linked to family
clusters, and almost all of them had epidemiological links to adult
patients.103
Outside of China, pediatric COVID-19 data from Asia are limited
at the time of writing these guidelines. To the best of our
knowledge, there are no critically ill children in countries such as
Japan and Singapore.
In India, children under 12 years of age constituted about 5.6%
(1378 out of 24,586) of the total COVID-19 cases reported from the
state of Tamil Nadu. In a limited screening of hospitalized children
with severe acute respiratory illness, 0.5% were diagnosed with
Table 2. Pharmacologic therapies.
Pharmacologic therapies under study in
adults for COVID-19
Optimal clinical timing




Interferons Days 4−7 of symptoms
Convalescent plasma In hospital
Anti-inflammatory Days 4–7 of symptoms
when ferritin > 500Corticosteroids (Methylprednisone)
Interleukin 1 Receptor Antagonist
Protein
Interleukin 6 inhibitor
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COVID-19.104 Critical illness is rare though a few deaths have been
reported in young infants.
The Institute of Epidemiology Disease Control and Research in
Bangladesh reports 102,292 confirmed COVID-19 cases in the
country with 3% being children under 10 years of age, 7% children
11−20 years of age, and with this age group accounting for 2.3%
of the total deaths in the country. No data on hospitalizations are
available.105
Europe
In Spain to date, of the 250,287 reported cases, 1399 children
under 15 years of age (0.6%) have tested COVID-19 positive, and
52 (3.7%) of those children required PICU admission.106 No
pediatric mortalities have occurred directly due to COVID-19, but
in 3 infected children SARS-CoV-2 may have contributed to their
death (Communication from Spanish Society of Pediatric Intensive
Care, SECIP, Registry for SARS-CoV-2 as of April 21, 2020).
In Italy, at the time of manuscript submission, of the 162,004
reported cases, 1.7% are children 0−18 years of age. Among the
pediatric patients, 18.2% were younger than 2 years of age and
the 65.3% were older than 6 years. Only 6.3% of the pediatric
patients required hospital admission with rare PICU admissions.107
In France, as of April 23, 556 pediatric patients (ages 0–14 years)
have required hospitalization, 20 of which have required PICU
admission, and 11 patients had underlying comorbidities. To date,
five deaths (ages 0–19 years) have been reported.108
North America
In North America, the Virtual PICU Systems (VPS) dashboard109
captures data for the United States and Canada from 183 PICUs. As
of June 18, VPS reports 653 COVID-19-positive pediatric patients
have required PICU admission and have in total required 4192
PICU days. The mortality rate is reported to be <1%. Of the
patients requiring PICU admission, 15% of patients were under 2
years of age, 27% were 2–12 years old, and 37% were 12–18 years
old with the remainder being adult patients admitted to the
PICUs. Of the patients with data on discharge, 45% were
previously healthy children with no comorbid conditions. Since
the VPS data are self-reported by PICUs, there may be inaccuracies
inherent to this dataset. Data from Mexico were not available.
South America
Similar to other regions of the world, definitive pediatric data were
difficult to identify. In South America, Brazil has been the most
affected country to date, followed by Peru, Chile, Ecuador,
Colombia, and Argentina. Data from Ministry of Health of Brazil
report, as of April 27, 27 deaths from COVID-19 in pediatric
patients (0–19 years old).110 The Brazilian Research Network in
Pediatric Intensive Care (BRnet-PIC network) initiated a COVID-19
patients study and has enrolled 37 PICUs. As of May 27, this study
included 32 confirmed pediatric critical care COVID-19 cases and
no deaths. Data from Ministry of Health of Argentina report 2571
confirmed COVID-19 pediatric patients (0–19 years old), and one
death as of May 24.111 The National Health Institute in Colombia
(INS—Instituto Nacional de Salud) reports 2790 confirmed pediatric
cases, 149 hospitalized patients, 31 PICU patients, and eight
deaths as of May 31. The Peruvian Ministry of Health reports 4350
confirmed pediatric patients and 18 as of May 19.112
CLINICAL TRIALS IN CHILDREN
Multiple pediatric clinical trials evaluating COVID-19 in children are
ongoing and can be identified at ClinicalTrials.gov113 with the
search criteria COVID-19, Children, and selecting for “Child (birth-
17)” under Eligibility Criteria. Among the 377 identified trails, 115
are interventional, 256 observational, and 43 are registries. Studies
are being conducted in all regions of the planet; pediatricians and
intensivists caring for children with COVID-19 and its sequalae are
encouraged to identify regional studies and registries for enrolling
patients. As this is a rapidly evolving disease entity, understanding
the demographics, clinical presentation, diagnostic findings,
biomarker profiles, and potentially effective treatments will be
beneficial for the global community of health-care providers.
CONCLUSION
This manuscript was developed to provide guidelines for
managing COVID-19-infected critically ill pediatric patients in
both high- and limited-resource settings. We also discuss the
available regional pediatric data, which may be of particular
interest given the limited pediatric COVID-19 data at present.
SARS-CoV-2 has had a devastating impact on the adult
population. Children comprise a small fraction of those
impacted by this disease. We propose a set of initial guidelines
to manage critically ill pediatric patients with COVID-19. These
guidelines were based on the best available evidence, extra-
polation of clinical evidence from adults, and the best practices
where the evidence is lacking. As the COVID-19 pandemic
evolves, implementing the proposed guidelines will help to
reduce morbidity and mortality in pediatric patients. Updating
these guidelines will be necessary based on additional data and
the new evidence from ongoing clinical trials.
ACKNOWLEDGEMENTS
The authors acknowledge Mahil Rao, M.D., Ph.D.; Ricarado Carbajal, M.D., Ph.D.;
Xinshu She, M.D.; Christopher Stave, M.L.S.; Andy Wen, M.D.
AUTHOR CONTRIBUTIONS
Substantial contributions to conception and design: S.K., K.J.S.A., J.C. Drafting, revising
and final approval of the article: S.K., M.J.C., F.G., E.M., X.Z., K.N., S.N., J.H.L., M.D.N., P.d.
l.O., C.K., K.J.S.A., D.C.d.S., V.S.L., J.C.
ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Coronavirus COVID-19 global cases by the Center for Systems Science and
Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.
edu/map.html (2020).
2. Dong, Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics
145, 1–10 (2020).
3. C. D. C. COVID-19 Response Team et al. Coronavirus disease 2019 in children—
United States, February 12–April 2, 2020. MMWR Morb. Mortal. Wkly. Rep. 69,
422–426 (2020).
4. Ogimi, C. et al. Characteristics and outcomes of coronavirus infection in children:
the role of viral factors and an immunocompromised state. J. Pediatr. Infect. Dis.
Soc. 8, 21–28 (2019).
5. Lu, X. et al. SARS-CoV-2 infection in children. N. Engl. J. Med. 382, 1663–1665
(2020).
6. Morand, A. et al. COVID-19 virus and children: what do we know? Arch. de.
Pédiatrie 27, 117–118 (2020).
7. Balasubramanian, S. et al. Coronavirus disease (COVID-19) in children—what we
know so far and what we do not? Indian Pediatr. 57, 435–442 (2020).
8. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus
in Wuhan, China. Lancet 395, 497–506 (2020).
9. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of
probable bat origin. Nature 579, 270–273 (2020).
10. Li, S.-R., Tang, Z.-J., Li, Z.-H. & Liu, X. Searching therapeutic strategy of new
coronavirus pneumonia from angiotensin-converting enzyme 2: the target of
COVID-19 and SARS-CoV. Eur. J. Clin. Microbiol. Infect. Dis. 39, 1021–1026 (2020).
11. South, A. M. et al. Controversies of renin-angiotensin system inhibition during
the COVID-19 pandemic. Nat. Rev. Nephrol. 395, 1054 (2020).
COVID-19 PICU guidelines: for high- and limited-resource settings
S Kache et al.
10
Pediatric Research _#####################_
12. Patel, S. K., Velkoska, E. & Burrell, L. M. Emerging markers in cardiovascular
disease: where does angiotensin-converting enzyme 2 fit in? Clin. Exp. Phar-
macol. Physiol. 40, 551–559 (2013).
13. Guang, C., Phillips, R. D., Jiang, B. & Milani, F. Three key proteases–angiotensin-I-
converting enzyme (ACE), ACE2 and renin–within and beyond the renin-
angiotensin system. Arch. Cardiovasc. Dis. 105, 373–385 (2012).
14. Zhu, L., Lu, X. & Chen, L. Possible causes for decreased susceptibility of children
to coronavirus. Pediatr. Res. 36, 344 (2020).
15. Song, R., Preston, G. & Yosypiv, I. V. Ontogeny of angiotensin-converting enzyme
2. Pediatr. Res. 71, 13–19 (2012).
16. Sampson, A. K., Moritz, K. M. & Denton, K. M. Postnatal ontogeny of angiotensin
receptors and ACE2 in male and female rats. Gend. Med. 9, 21–32 (2012).
17. Bénéteau-Burnat, B. et al. Serum angiotensin-converting enzyme in healthy and
sarcoidotic children: comparison with the reference interval for adults. Clin.
Chem. 36, 344–346 (1990).
18. Henry, B. M., Lippi, G. & Plebani, M. Laboratory abnormalities in children with
novel coronavirus disease 2019. Clin. Chem. Lab. Med. 0, 415 (2020).
19. Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-
nCoV/SARS-CoV-2. Cell Discov. 6, 1–18 (2020).
20. Bubenik, G. A. & Konturek, S. J. Melatonin and aging: prospects for human
treatment. J. Physiol. Pharmacol. 62, 13–19 (2011).
21. World Health Organization. Pocket Book for Hospital Care of Children: Guidelines
for the Management of Common Illness with Limited Resources (World Health
Organization, Geneva, 2013).
22. Riviello, E. D. et al. Hospital incidence and outcomes of the acute respiratory
distress syndrome using the Kigali modification of the Berlin definition. Am. J.
Respir. Crit. Care Med. 193, 52–59 (2016).
23. Cheifetz, I. M. Pediatric ARDS. Respir. Care 62, 718–731 (2017).
24. World Health Organization. Oxygen Therapy for Children: A Manual for Health
Workers (World Health Organization, Geneva). http://www.who.int/
maternal_child_adolescent/documents/child-oxygen-therapy/en/ (2016).
25. World Health Organization. Clinical management of severe acute respiratory
infection (SARI) when COVID-19 disease is suspected. https://www.who.int/
publications-detail/clinical-management-of-severe-acute-respiratory-infection-
when-novel-coronavirus-(ncov)-infection-is-suspected (2020).
26. Chisti, M. J. et al. Bubble continuous positive airway pressure for children with
severe pneumonia and hypoxaemia in Bangladesh: an open, randomised con-
trolled trial. Lancet 386, 1057–1065 (2015).
27. Ekhaguere, O. A., Mairami, A. B. & Kirpalani, H. Risk and benefits of Bubble
Continuous Positive Airway Pressure for neonatal and childhood respiratory
diseases in Low- and Middle-Income countries. Paediatr. Respir. Rev. 29, 31–36
(2019).
28. Wilson, P. T. et al. Continuous positive airway pressure for children with undif-
ferentiated respiratory distress in Ghana: an open-label, cluster, crossover trial.
Lancet Glob. Health 5, e615–e623 (2017).
29. Luo, J. et al. Efficacy of high-flow nasal cannula vs standard oxygen therapy or
nasal continuous positive airway pressure in children with respiratory distress: a
meta-analysis. J. Pediatrics 215, 199–208.e8 (2019).
30. Matava, C. T. et al. Pediatric airway management in COVID-19 patients—Con-
sensus Guidelines from the Society for Pediatric Anesthesia’s Pediatric Difficult
Intubation Collaborative and the Canadian Pediatric Anesthesia Society. Anesth.
Analg. 1, 61–73 (2020).
31. Hall, D. et al. Videolaryngoscopy increases “mouth-to-mouth” distance com-
pared with direct laryngoscopy. Anaesthesia 120, 173 (2020).
32. Anesthesia Patient Safety Foundation. Perioperative consideration for the
2019 novel coronavirus (COVID-19). https://www.apsf.org/news-updates/
perioperative-considerations-for-the-2019-novel-coronavirus-covid-19/ (2020).
33. Canelli, R. et al. Barrier enclosure during endotracheal intubation. N. Engl. J. Med.
382, 1957–1958 (2020).
34. D’Silva, D. F. et al. Extubation of patients with COVID-19. Br. J. Anaesth. 125,
e192–e195 (2020).
35. Rimensberger, P. C., Cheifetz, I. M. & Pediatric Acute Lung Injury Consensus
Conference Group. Ventilatory support in children with pediatric acute
respiratory distress syndrome: Proceedings from the Pediatric Acute Lung Injury
Consensus Conference. Pediatr. Crit. Care Med. 16, S51−S60 (2015).
36. Santschi, M. et al. Acute lung injury in children: therapeutic practice and feasi-
bility of international clinical trials. Pediatr. Crit. Care Med. 11, 681–689 (2010).
37. de Jager, P. et al. Tidal volume and mortality in mechanically ventilated children:
a systematic review and meta-analysis of observational studies. Crit. Care Med.
42, 2461–2472 (2014).
38. Imber, D. A., Thomas, N. J. & Yehya, N. Association between tidal volumes
adjusted for ideal body weight and outcomes in pediatric acute respiratory
distress syndrome. Pediatr. Crit. Care Med. 20, e145–e153 (2019).
39. Gattinoni, L. et al. Covid-19 does not lead to a “typical” acute respiratory distress
syndrome. Am. J. Respir. Crit. Care Med. 201, 1299–1300 (2020).
40. Guérin, C. et al. Prone positioning in severe acute respiratory distress syndrome.
N. Engl. J. Med. 368, 2159–2168 (2013).
41. Tamburro, R. F., Kneyber, M. C. J. & Pediatric Acute Lung Injury Consensus
Conference Group. Pulmonary specific ancillary treatment for pediatric acute
respiratory distress syndrome: Proceedings from the Pediatric Acute Lung Injury
Consensus Conference. Pediatr. Crit. Care Med. 16, S61−S72 (2015).
42. Gattinoni, L. et al. COVID-19 pneumonia: different respiratory treatments for
different phenotypes? Intensive Care Med. 382, 727 (2020).
43. de Souza, T. H., Nadal, J. A., Nogueira, R. J., Pereira, R. M. & Brandão, M. B. Clinical
manifestations of children with COVID-19: a systematic review. Pediatr. Pulmo-
nol. 1–8 (2020).
44. Madjid, M., Safavi-Naeini, P., Solomon, S. D., & Vardeny, O. Potential effects of
coronaviruses on the cardiovascular system: a review. JAMA Cardiol. https://doi.
org/10.1001/jamacardio.2020.1286 (2020).
45. Inciardi, R. M. et al. Cardiac involvement in a patient with coronavirus disease
2019 (COVID-19). JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.1096
(2020).
46. Atri, D. et al. COVID-19 for the cardiologist: a current review of the virology,
clinical epidemiology, cardiac and other clinical manifestations and potential
therapeutic strategies. JACC Basic Transl. Sci. 5, 518–536 (2020).
47. Weiss, S. L. et al. Surviving sepsis campaign international guidelines for the
management of septic shock and sepsis-associated organ dysfunction in chil-
dren. Pediatr. Crit. Care Med. 21, e52–e106 (2020).
48. Inwald, D. P. et al. Restricted fluid bolus volume in early septic shock: results of
the Fluids in Shock pilot trial. Arch. Dis. Child 104, 426–431 (2019).
49. Santhanam, I. et al. A prospective randomized controlled study of two fluid
regimens in the initial management of septic shock in the emergency depart-
ment. Pediatr. Emerg. Care 24, 647–655 (2008).
50. Sankar, J. et al. Fluid bolus over 15−20 versus 5−10min each in the first hour of
resuscitation in children with septic shock: a randomized controlled trial. Pediatr.
Crit. Care Med. 18, e435–e445 (2017).
51. Maitland, K. et al. Mortality after fluid bolus in African children with severe
infection. N. Engl. J. Med. 364, 2483–2495 (2011).
52. Schlapbach, L. J. et al. Prediction of pediatric sepsis mortality within 1 h of
intensive care admission. Intensive Care Med. 43, 1085–1096 (2017).
53. Jansen, T. C. et al. Early lactate-guided therapy in intensive care unit patients: a
multicenter, open-label, randomized controlled trial. Am. J. Respir. Crit. Care Med.
182, 752–761 (2010).
54. Lyu, X. et al. [Efficacies of fluid resuscitation as guided by lactate clearance rate
and central venous oxygen saturation in patients with septic shock]. Zhonghua
Yi Xue Za Zhi 95, 496–500 (2015).
55. Jones, A. E. et al. Lactate clearance vs central venous oxygen saturation as
goals of early sepsis therapy: a randomized clinical trial. JAMA 303, 739–746
(2010).
56. Zhou, X. et al. Use of stepwise lactate kinetics-oriented hemodynamic therapy
could improve the clinical outcomes of patients with sepsis-associated hyper-
lactatemia. Crit. Care 21, 33 (2017).
57. Hu, H., Ma, F., Wei, X., & Fang, Y. Coronavirus fulminant myocarditis saved with
glucocorticoid and human immunoglobulin. Eur. Heart J. https://doi.org/
10.1093/eurheartj/ehaa190 (2020).
58. Misra, D. P., Agarwal, V., Gasparyan, A. Y. & Zimba, O. Rheumatologists’ per-
spective on coronavirus disease 19 (COVID-19) and potential therapeutic tar-
gets. Clin. Rheumatol. 11, 65 (2020).
59. Menendez, J. J. et al. Incidence and risk factors of superficial and deep vein
thrombosis associated with peripherally inserted central catheters in children. J.
Thromb. Haemost. 14, 2158–2168 (2016).
60. Raffini, L., Huang, Y. S., Witmer, C. & Feudtner, C. Dramatic increase in venous
thromboembolism in children’s hospitals in the United States from 2001 to
2007. Pediatrics 124, 1001–1008 (2009).
61. Ramsi, M. & Al Ali, A. S. Thrombocytopenia-associated multiple-organ failure
(TAMOF): recognition and management. BMJ Case Rep. 2018, bcr-2018-225594
(2018).
62. Nguyen, T. C. et al. Intensive plasma exchange increases a disintegrin and
metalloprotease with thrombospondin motifs-13 activity and reverses organ
dysfunction in children with thrombocytopenia-associated multiple organ fail-
ure. Crit. Care Med. 36, 2878–2887 (2008).
63. Xie, Y., Wang, X., Yang, P. & Zhang, S. COVID-19 complicated by acute pulmonary
embolism. Radiol.: Cardiothorac. Imaging 2, e200067 (2020).
64. Tang, N., Li, D., Wang, X. & Sun, Z. Abnormal coagulation parameters are asso-
ciated with poor prognosis in patients with novel coronavirus pneumonia. J.
Thromb. Haemost. 18, 844–847 (2020).
65. Li, T., Lu, H. & Zhang, W. Clinical observation and management of COVID-19
patients. Emerg. Microbes Infect. 9, 687–690 (2020).
66. Klok, F. A. et al. Incidence of thrombotic complications in critically ill ICU patients
with COVID-19. Thromb. Res. 191, 145–147 (2020).
COVID-19 PICU guidelines: for high- and limited-resource settings
S Kache et al.
11
Pediatric Research _#####################_
67. Han, H. et al. Prominent changes in blood coagulation of patients with SARS-
CoV-2 infection. Clin. Chem. Lab. Med. 0, 3 (2020).
68. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with
2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061
(2020).
69. Liu, W. et al. Detection of Covid-19 in children in early January 2020 in Wuhan,
China. N. Engl. J. Med. 382, 1370–1371 (2020).
70. Ong, J. S. M. et al. Coronavirus disease 2019 in critically ill children: a narrative
review of the literature. Pediatr. Crit. Care Med. 1, 607–619 (2020).
71. Sun, D. et al. Clinical features of severe pediatric patients with coronavirus
disease 2019 in Wuhan: a single center’s observational study. World J. Pediatrics
395, 1–9 (2020).
72. Liu, P. P., Blet, A., Smyth, D., & Li, H. The science underlying COVID-19: impli-
cations for the cardiovascular system. Circulation 142, 68–78 (2020).
73. Yang, Y. & Tang, H. Aberrant coagulation causes a hyper-inflammatory response
in severe influenza pneumonia. Cell. Mol. Immunol. 13, 432–442 (2016).
74. Yin, S., Huang, M., Li, D. & Tang, N. Difference of coagulation features between
severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J. Thromb.
Thrombolysis 395, 507 (2020).
75. Tang, N. et al. Anticoagulant treatment is associated with decreased mortality in
severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Hae-
most. 18, 1094–1099 (2020).
76. Keith, P. et al. A novel treatment approach to the novel coronavirus: an argu-
ment for the use of therapeutic plasma exchange for fulminant COVID-19. Crit.
Care 24, 128 (2020).
77. Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients
with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis.
52, 447–456 (2011).
78. Kain, T. et al. Pharmacologic treatments and supportive care for Middle East
respiratory syndrome. Emerg. Infect. Dis. 26, 1814 (2020).
79. Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong
Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).
80. Chen, L., Xiong, J., Bao, L. & Shi, Y. Convalescent plasma as a potential therapy
for COVID-19. Lancet Infect. Dis. 20, 398–400 (2020).
81. Martindale, R., Patel, J., Taylor, B., Warren, M. & McClave S. Nutrition therapy in
the patient with COVID-19 disease requiring ICU care. https://www.sccm.org/
getattachment/Disaster/Nutrition-Therapy-COVID-19-SCCM-ASPEN.pdf?
lang=en-US (2020).
82. Wang, L. et al. Coronavirus disease 19 infection does not result in acute kidney
injury: an analysis of 116 hospitalized patients from Wuhan, China. Am. J.
Nephrol. 51, 1–6 (2020).
83. Alhazzani, W. et al. Surviving sepsis campaign: guidelines on the management
of critically ill adults with coronavirus disease 2019 (COVID-19). Crit. Care Med. 1,
1–32 2020.
84. Edelson, D. P. et al. Interim guidance for basic and advanced life support in
adults, children, and neonates with suspected or confirmed COVID-19: From the
Emergency Cardiovascular Care Committee and Get With the Guidelines
®-Resuscitation Adult and Pediatric Task Forces of the American Heart Asso-
ciation in Collaboration with the American Academy of Pediatrics, American
Association for Respiratory Care, American College of Emergency Physicians,
The Society of Critical Care Anesthesiologists, and American Society of Anes-
thesiologists: Supporting Organizations: American Association of Critical Care
Nurses and National EMS Physicians. Circulation 395, 497–18 (2020).
85. ECRI Institute. Mechanical ventilation of SARS patients: lessons from the 2003
SARS outbreak. Health Devices. https://www.ecri.org/components/HDJournal/
Pages/Mechanical-Ventilation-of-SARS-Patients-2003-SARS-Outbreak.aspx?tab=2
(2020).
86. Mazer, S. P. et al. Reverse CPR: a pilot study of CPR in the prone position.
Resuscitation 57, 279–285 (2003).
87. Bartlett, R. H. et al. Initial ELSO Guidance Document: ECMO for COVID-19
patients with severe cardiopulmonary failure. ASAIO J. 1, 472–474 (2020).
88. Henry, B. M. & Lippi, G. Poor survival with extracorporeal membrane oxygena-
tion in acute respiratory distress syndrome (ARDS) due to coronavirus disease
2019 (COVID-19): pooled analysis of early reports. J. Crit. Care 58, 27–28 (2020).
89. Shekar, K. et al. Extracorporeal life support organization COVID-19 interim
guidelines. ASAIO J. 1–15 (2020). Online ahead of print.
90. ELSO. ELSO guidelines for extracorporeal life support. https://www.elso.org/
Resources/Guidelines.aspx (2017).
91. ELSO. ELSO Guidance Document: ECMO for COVID-19 patients with severe
cardiopulmonary failure. https://www.elso.org/Portals/0/Files/pdf/ECMO%20for
%20COVID%2019%20Guidance%20Document.Final%2003.24.2020.pdf (2020).
92. Henry, B. M. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet
Respir. Med. 8, e24 (2020).
93. CDC Health Alert. Multisystem inflammatory syndrome in children (MIS-C)
associated with coronavirus disease 2019 (COVID-19). May 14. https://
emergency.cdc.gov/han/2020/han00432.asp (2020).
94. Balasubramanian, S., Nagendran, T. M., Ramachandran, B. & Ramanan, A. V.
Hyper-inflammatory syndrome in a child with COVID-19 treated successfully
with intravenous immunoglobulin and tocilizumab. Indian Pediatr. 1–5 (2020).
Online ahead of print.
95. Gamez-Gonzalez, L. B. et al. Kawasaki disease shock syndrome: unique and
severe subtype of Kawasaki disease. Pediatr. Int. 60, 781–790 (2018).
96. Riphagen, S. et al. Hyperinflammatory shock in children during COVID-19 pan-
demic. Lancet 395, 1607–1608 (2020).
97. Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian
epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet
395, 1771–1778 (2020).
98. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients
with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395,
1054–1062 (2020).
99. Coronavirus disease 2019 (COVID-19) treatment guidelines. https://
covid19treatmentguidelines.nih.gov/ (2020).
100. Republic of Uganda COVID-19 Response Info Hub. https://covid19.gou.go.ug
(2020).
101. National Health Commission of the People’s Republic of China. Coronavirus
disease 2019 (COVID-19) situation reports. http://www.nhc.gov.cn/xcs/yqtb/
202004/5b4216ebda6f4d2a884ef6217f32c8fb.shtml (2020).
102. Pediatrics Branch of Hubei Medical Association. A letter from Pediatrics Branch
of Hubei Medical Association to The National Pediatric Colleagues. http://www.
hbma.org.cn/qt/cont/news-537.html (2020).
103. Shen, Q. et al. Novel coronavirus infection in children outside of Wuhan, China.
Pediatr. Pulmonol. 323, 707 (2020).
104. Gupta, N. et al. Severe acute respiratory illness surveillance for coronavirus
disease 2019, India. Indian J. Med. Res. 151, 236–240 (2020).
105. Institute of Epidemiology, Disease Control and Research Bangladesh COVID-19
Update. https://www.iedcr.gov.bd (2020).
106. Red Nacional de Vigilancia Epidemiológica. Informe Sobre La Situación de
COVIE-19 en España 2020. https://www.isciii.es/QueHacemos/Servicios/
VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/
InformesCOVID-19.aspx (2020).
107. EpiCentro. COVID-19 integrated surveillance: key national data. https://www.
epicentro.iss.it/en/coronavirus/sars-cov-2-integrated-surveillance-data (2020).




109. COVID-19 data: North America Pediatric ICUs. https://covid19.myvps.org/
(2020).
110. COVID-19 Boletim Epidemiológico Diário, Brasília. https://www.saude.gov.br/
images/pdf/2020/April/27/2020-04-27-COVID-19-COLETIVA.pdf (2020).
111. Coronavirus COVD-19 conocé información y recomendaciones del Ministerio de
Salud. https://www.argentina.gob.ar/ (2020).
112. Covid 19 en el Perú—Ministerio del Salud. https://covid19.minsa.gob.pe/index.
asp (2020).
113. NIH U.S. National Library of Medicine ClinicalTrials.gov. https://clinicaltrials.gov/
ct2/home (2020).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2020
COVID-19 PICU guidelines: for high- and limited-resource settings
S Kache et al.
12
Pediatric Research _#####################_
